Ann: Trading halt, page-570

hopefully that is what the FDA are seeing infront of them now, and have asked MSB to fast track under warp speed with so many dying. the FDA need to make a solid case towards to get this to happen as Si and MSB has stated, that he wants the trail to run full course with numbers... as he does not want the trial to stop because he has a secondary endpoint with this trial, (you will hear this in the last persentation) which is to address long covid, and this will be a major difference to many other treatments. the secondary end point is a 12 month followup, to see if organ repair is had, the side effect of long covid now even found in other wise healthy non symptomatic covid cases with multiple organ issue, but more so heart and in this approach to validate the secondary end point he would like the numbers to have overwhelming data to the FDA (so they can't find another excuse) as sometimes it is a point of reference for the FDA "oh you don't have the number to be showing significance in your findings"... so another long trial ....youhave to be kidding..The significancy of long covid, and more important what our stem cells will do in organ repair over time has many applications no just over long covid, its is the basis of stem cell therapy and MSB- repairing the body.it is sad that people will have to die, if the trial is run to its full length if OE is given. Somehow they need to find a solution for both...maybe get the FDA to change the endpiont or allow it to be melded/blended into current trials... they have changed the goal post against us before, now they can do it in favour... political pressure, and warp speed might influence but it seems to me it hasn''t done before- more like big pharma agendas at play to keep stem cells and MSB out. ..come on Novartis push a few buttons